Neoepitope prediction in murine B cell lymphoma

Neoepitopes, tumor-specific antigens that arise from somatic mutations, are increasingly recognized as critical cancer immunotherapy targets. Thus, identifying immunogenic neoepitopes allows the assessment of endogenous anti-tumor responses and identifying clinically relevant immunotherapies. The aim of this project was to identify novel neoepitope candidates in the A20 murine B cell lymphoma cell line, through whole exome and RNA sequencing. By using ex vivo assays we identified immunogenic neoepitopes and showed that neoepitope-specific T cell responses can be induced in vivo by in situ vaccination in the A20 murine lymphoma model.